Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203762 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL4206117 | 0.89 | KCNH2 (1.00) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL4202111 | 0.89 | KCNH2 (1.00) | KCNH2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL4358406 | 0.88 | KCNH2 (0.98) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL4216135 | 0.84 | KCNH2 (0.71) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL4206093 | 0.84 | KCNH2 (0.71) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL8053911 | 0.83 | SLC6A3 (0.72) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL5022877 | 0.80 | KCNH2 (0.52) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL8588993 | 0.78 | ADRB2 (0.61) | KCNH2SLC6A2SLC6A3 | |
| SCHEMBL13948498 | 0.78 | ADRB3 (0.78) | KCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2009-01-22 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | GRIN1, GRIA4, GRIA1 | KCNH2 287/4885SLC6A2 2149/4885SLC6A3 2166/4885 |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | KCNH2 382/4885SLC6A2 2030/4885SLC6A3 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.